PLEASE NOTE: Before proceeding to the CE/CME program, you must first "Sign In" or "Sign Up" in the top right corner.
FORMAT: Complimentary CE/CME Webcast
MAXIMUM CREDITS: Earn Up to 1.5 CPEUs, 1.5 Contact Hours, or 1.5 AMA PRA Category 1 Credits™
Please click on the appropriate link to review the CE/CME information, view the CE/CME webcast, and receive your credit:
If you are a DIETITIAN: Click Here
If you are a PHARMACIST: Click Here
If you are a PHYSICIAN: Click Here
If you are a NURSE: Click Here
If you are an ADVANCED PRACTICE REGISTERED NURSE: Click Here
RELEASE DATE: July 22, 2019
EXPIRATION DATE: July 31, 2020
Research shows that intravenous lipid emulsions (ILEs) that incorporate lipid sources other than soybean oil can improve the risk/benefit ratio and outcomes of patients who require parenteral nutrition, including those who are critically ill. Alternative options have been used in Europe and around the world, and have recently expanded into the United States. On a physiologic level, the ratio of soybean, fish, and olive oils contained in various ILEs affects the omega-6 fatty acid content, which is associated with liver injury and inflammation. In contrast, recent meta-analyses have compared clinical outcomes of patients receiving fish, mixed, and soybean oil ILEs and concluded that hospital length of stay, liver function, and mortality are improved when sources of omega-3 fatty acid are used in place of or in addition to soybean oil. Initiating a switch between ILEs requires an individualized approach that takes patient-specific factors into consideration. In addition, overcoming formulary restrictions requires thoughtful analysis and demonstration of institution-specific need. The desired result of this activity is to prepare clinicians to incorporate new evidence-based parenteral nutrition strategies into practice while maximizing safety and optimizing clinical outcomes.
Jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC
This activity is supported by an independent educational grant from Fresenius Kabi USA.